Clinical Trial Detail

NCT ID NCT03574649
Title QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors NantKwest, Inc.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Cisplatin + Docetaxel + Paclitaxel

Aldoxorubicin + ALT-803 + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Paclitaxel

Age Groups: adult senior

No variant requirements are available.